All Title Author
Keywords Abstract

Should I Get Screened for Sleeping Sickness? A Qualitative Study in Kasai Province, Democratic Republic of Congo

DOI: 10.1371/journal.pntd.0001467

Full-Text   Cite this paper   Add to My Lib


Background Control of human African trypanosomiasis (sleeping sickness) in the Democratic Republic of Congo is based on mass population active screening by mobile teams. Although generally considered a successful strategy, the community participation rates in these screening activities and ensuing treatment remain low in the Kasai-Oriental province. A better understanding of the reasons behind this observation is necessary to improve regional control activities. Methods Thirteen focus group discussions were held in five health zones of the Kasai-Oriental province to gain insights in the regional perceptions regarding sleeping sickness and the national control programme's activities. Principal Findings Sleeping sickness is well known among the population and is considered a serious and life-threatening disease. The disease is acknowledged to have severe implications for the individual (e.g., persistence of manic periods and trembling hands, even after treatment), at the family level (e.g., income loss, conflicts, separations) and for communities (e.g., disruption of community life and activities). Several important barriers to screening and treatment were identified. Fear of drug toxicity, lack of confidentiality during screening procedures, financial barriers and a lack of communication between the mobile teams and local communities were described. Additionally, a number of regionally accepted prohibitions related to sleeping sickness treatment were described that were found to be a strong impediment to disease screening and treatment. These prohibitions, which do not seem to have a rational basis, have far-reaching socio-economic repercussions and severely restrict the participation in day-to-day life. Conclusions/Significance A mobile screening calendar more adapted to the local conditions with more respect for privacy, the use of less toxic drugs, and a better understanding of the origin as well as better communication about the prohibitions related to treatment would facilitate higher participation rates among the Kasai-Oriental population in sleeping sickness screening and treatment activities organized by the national HAT control programme.


[1]  WHO (1998) La Trypanosomiase Africaine: lute et surveillance. 881 p. Rapport d'un comité d'experts de l'OMS.
[2]  WHO (2006) Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec 81: 71–80.
[3]  Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, et al. (2010) The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 9: 57. 1476-072X-9-57 [pii];10.1186/1476-072X-9-57 [doi]. doi: 10.1186/1476-072X-9-57
[4]  Burke J (2000) La trypanosomiase humaine africaine. Brussels: Fonds Médical Tropical. 39 p.
[5]  Burke J (1992) Les trypanosomiasis Africaines. In: Janssens PG, Kivits M, Vuylsteke J, editors. Médecine et Hygiène en Afrique Centrale de 1885 à nos jours. Brussels: Fondation Roi Baudouin. pp. 1489–1495.
[6]  Simarro PP, Sima FO, Mir M, Mateo MJ, Roche J (1991) [Control of human African trypanosomiasis in Luba in equatorial Guinea:evaluation of three methods]. Bull World Health Organ 69: 451–457.
[7]  Stanghellini A (1999) Prophylactic strategies in human African trypanosomiasis. In: Dumas M, Bouteille B, Buguet A, editors. Progress in human African trypanosomiasis, sleeping sickness. Paris: Springer. pp. 301–313.
[8]  Moore A, Richer M, Enrile M, Losio E, Roberts J, et al. (1999) Resurgence of sleeping sickness in Tambura County, Sudan. Am J Trop Med Hyg 61: 315–318.
[9]  Moore A, Richer M (2001) Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health 6: 342–347. tmi714 [pii]. doi: 10.1046/j.1365-3156.2001.00714.x
[10]  Paquet C, Castilla J, Mbulamberi D, Beaulieu MF, Gastellu Etchegorry MG, et al. (1995) [Trypanosomiasis from Trypanosoma brucei gambiense in the center of north-west Uganda. Evaluation of 5 years of control (1987–1991)]. Bull Soc Pathol Exot 88: 38–41.
[11]  Lutumba P, Robays J, Miaka mia BC, Mesu VK, Molisho D, et al. (2005) Trypanosomiasis control, Democratic Republic of Congo, 1993–2003. Emerg Infect Dis 11: 1382–1388. doi: 10.3201/eid1109.041020
[12]  Robays J, Bilengue MM, Van der Stuyft P, Boelaert M (2004) The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health 9: 542–550. 10.1111/j.1365-3156.2004.01240.x [doi];TMI1240 [pii]. doi: 10.1111/j.1365-3156.2004.01240.x
[13]  Robays J, Nyamowala G, Sese C, Kande V, Lutumba P, et al. (2008) High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo. Emerg Infect Dis 14: 966–967. doi: 10.3201/eid1406.071266
[14]  Pépin J, Bokelo M (2005) Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001. Emerg Infect Dis 11: 921–7. doi: 10.3201/eid1106.050036
[15]  PNLTHA (2007) Rapport annuel du programme national de lutte contre la THA en RDC.
[16]  Robays J, Lefevre P, Lutumba P, Lubanza S, Kande Betu KM, et al. (2007) Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 12: 290–298. TMI1768 [pii];10.1111/j.1365-3156.2006.01768.x [doi]. doi: 10.1111/j.1365-3156.2006.01768.x
[17]  CTB, PNLTHA (2004) Dossier Technique et Financier :Appui à la lutte contre la Trypanosomiase Humaine Africaine, phase 3, 2003–2008, rapport de formulation.
[18]  Asonganyi T, Ade S (1994) Sleeping sickness in Cameroon. Journal Camerounais de Médecine 3: 30–37.
[19]  Pepin J, Mpia B, Iloasebe M (2002) Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment. Trans R Soc Trop Med Hyg 96: 421–426. doi: 10.1016/S0035-9203(02)90380-9
[20]  Bureau Central de la Trypanosomiase (1995) Guide Technique du Programme National de lutte contre la THA en RD Congo.
[21]  Bailey EJ (2000) Medical Anthropology and African American Health. Westport: Bergin & Garvey. 270 p.
[22]  Beardsworth A, Keil T (1997) Sociology on the Menu: An Invitation to the Study of Food and Society. London: Routledge. 288 p.
[23]  Manderson L (1987) Hot-cold food and medical theories: overview and introduction. Soc Sci Med 25: 329–330. doi: 10.1016/0277-9536(87)90270-X
[24]  Burri C, Brun R (2003) Human African Trypanosomiasis. In: Cook GC, Zumla A, editors. Mansons's Tropical Diseases 21st ed. London: Saunders. pp. 1303–1323.
[25]  Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6: 390–400. doi: 10.1046/j.1365-3156.2001.00710.x
[26]  Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155–1171. 0707354 [pii];10.1038/sj.bjp.0707354 [doi]. doi: 10.1038/sj.bjp.0707354
[27]  Yun O, Priotto G, Tong J, Flevaud L, Chappuis F (2010) NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4: e720. 10.1371/journal.pntd.0000720 [doi]. doi: 10.1371/journal.pntd.0000720


comments powered by Disqus